Compare NTNX & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTNX | RDY |
|---|---|---|
| Founded | 2009 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 11.8B |
| IPO Year | 2015 | 2001 |
| Metric | NTNX | RDY |
|---|---|---|
| Price | $55.04 | $11.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 1 |
| Target Price | ★ $62.29 | $16.90 |
| AVG Volume (30 Days) | ★ 3.3M | 3.1M |
| Earning Date | 05-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | ★ 227.45 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $2,537,927,000.00 | N/A |
| Revenue This Year | $13.44 | $7.72 |
| Revenue Next Year | $13.03 | $3.50 |
| P/E Ratio | $64.18 | ★ $18.67 |
| Revenue Growth | ★ 18.11 | N/A |
| 52 Week Low | $34.01 | $11.36 |
| 52 Week High | $82.42 | $15.67 |
| Indicator | NTNX | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 32.74 |
| Support Level | $44.85 | N/A |
| Resistance Level | $58.65 | $13.96 |
| Average True Range (ATR) | 2.30 | 0.39 |
| MACD | -0.25 | -0.21 |
| Stochastic Oscillator | 39.83 | 15.77 |
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.